We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Respiratory

Refining COPD Exacerbation Risk Categories Enhances Prediction of Future Episodes

MedXY Editorial Team•Aug 20, 2026•Respiratory
COPDexacerbationsRisk PredictionClinical Utility

Highlight

  • The standard COPD exacerbation risk definition (≥2 moderate or ≥1 severe exacerbation in the past year) has limited discriminative power.
  • In both COPDGene and NOVELTY cohorts, considering any moderate or severe exacerbation within the prior two years yielded superior accuracy (AUC up to 0.87) for predicting future exacerbations.
  • Using rolling two-year exacerbation windows also provided the highest clinical utility across relevant treatment thresholds (5%-30%) for initiating or intensifying therapy.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Technical and Clinical Feasibility of a Pulmonary Telerehabilitation Model for People with COPD: A Comprehensive ReviewThis review synthesizes evidence on the feasibility, acceptance, and clinical outcomes of pulmonary telerehabilitation models in COPD, highlighting technical reliability, patient adherence, and clinical benefits from recent trials, includinOct 18, 2026Integrating Polygenic Risk Scores and Lifestyle Factors to Predict Type 2 Diabetes Onset in the Japanese PopulationThis study demonstrates that polygenic risk scores (PRS) independently predict type 2 diabetes risk in Japanese individuals, and healthy lifestyles can mitigate this risk even among genetically predisposed people, enhancing personalized preOct 12, 2026Quantifying the Surgeon’s Intuition: Visual Analog Scale as a Predictor of Postoperative OutcomesSurgeons’ preoperative subjective assessments quantified by visual analog scale significantly predict severe postoperative complications, enhancing traditional risk models for better perioperative prognosis.Oct 10, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Sputum Cellularity and Health Services Utilization in Asthma and COPD: Insights into Inflammatory Phenotypes and Clinical Outcomes
Sputum eosinophilia is linked to increased asthma-specific health services use, while neutrophilic inflammation drives hospitalizations in COPD. Understanding these inflammatory patterns aids personalized management and resource planning.
Oct 8, 2026
Airway Mucus Plugs on CT: Predicting Respiratory Outcomes in COPD and Preserved Spirometry — Insights from a Chinese CohortThis prospective Chinese cohort study found that airway mucus plugs on chest CT are linked to increased risk of exacerbations and COPD development, even in individuals with preserved spirometry, highlighting their prognostic value in early Sep 30, 2026
Predicting Lung Function Decline in COPD via One-Year CT Emphysema Subtype Progression: Insights from SPIROMICSSPIROMICS study demonstrates that progression of CT-detected emphysema subtypes over one year independently predicts accelerated FEV₁ decline, offering valuable intermediate endpoints for COPD clinical trials.Sep 29, 2026